Research programme: cancer therapeutics - Merck/Cancer Research Technology/iOnctura

Drug Profile

Research programme: cancer therapeutics - Merck/Cancer Research Technology/iOnctura

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research Technology; Merck AG
  • Developer Cancer Research Technology; iOnctura; Merck AG
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Immunostimulants; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Nov 2017 iOnctura plans a clinical trial for the selective phosphatidylinositol-3 kinase delta inhibitor for Cancer in 2018
  • 20 Jun 2017 iOnctura and Cancer Research Technology enter into collaboration to develop three therapeutics for Cancer
  • 20 Jun 2017 Preclinical trials in Cancer in Switzerland (unspecified route) (iOnctura pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top